Equity Issuances

Creative Media & Community Trust Corp issued 850,885 shares of Common Stock of common stock to holders of Series A1 Preferred Stock for in lieu of cash payment for the redemption of 322,283 shares of Series A1 Preferred Stock, including accrued and unpaid dividends.

“On November 19, 2025, Creative Media & Community Trust Corporation (the “Company”) authorized the issuance of 850,885 shares of Common Stock in respect of redemptions of the Company’s Series A1 Preferred Stock, par value $0.001 (the “Series A1 Preferred Stock”), in lieu of cash payment for the redemption of 322,283 shares of Series A1 Preferred Stock, including accrued and unpaid dividends.”

SURMODICS INC issued common stock.

“sting the deregistration of the Company Common Stock under Section 12(g) of the Exchange Act and the suspension of the Company’s reporting obligations under Sections 13 and 15(d) of the Exchange Act. Item 3.03 Material Modification to Rights of Security Holders. The information set forth in the Introductory Note,”

Chiron Real Estate Inc. issued 2,000,000 shares of its 8.00% Series B cumulative redeemable preferred stock of preferred stock to Raymond James & Associates, Inc., BMO Capital Markets Corp., Stifel, Nicolaus & Company, Incorporated and Robert W. Baird & Co. Incorporated for $25.00 per share.

“the Company filed Articles Supplementary with the Maryland State Department of Assessments and Taxation to designate 2,300,000 shares of the Company’s authorized preferred stock as shares of 8.00% Series B Cumulative Redeemable Preferred Stock, par value $0.001 per share, with a liquidation preference of $25.00 per share (“Series B Preferred Stock"), with the powers, preferences and privileges as set forth in the Articles Supplementary”

ExchangeRight Income Fund issued 18,315 of common stock to unknown for $500,000.

“Rule 506(c) of Regulation D promulgated thereunder. The following table details the shares sold: Number of Gross Share Class Shares Sold Proceeds Class D Common Shares 18,315 $ 500,000 Forward-Looking Statements Certain statements contained in this Current Report on Form 8-K other than historical facts may be considered “forward-looking statements,” and, as”

ChargePoint Holdings, Inc. issued subject to a cap of 19.99% of the Company’s outstanding shares of common stock to holders of the Senior Secured Loans for payment of interest in shares of common stock.

“the Borrower may elect to pay the interest in shares of common stock of the Company (“Interest Shares”), valued based on the 30-day VWAP preceding the applicable interest payment date.”

ChargePoint Holdings, Inc. issued 1,671,000 shares of the Company's common stock of warrant to Exchanging Holders for no cash proceeds.

“the Company issued Warrants to purchase an aggregate of 1,671,000 shares of the Company’s common stock (the “Warrant Shares”) to the Exchanging Holders.”

Perella Weinberg Partners issued 1,320,319 shares of common stock to certain limited partners of PWP OpCo for in exchange for 1,319,000 Class A partnership units of PWP OpCo and 1,319,000 shares of Class B common stock.

“On November 17, 2025 , Perella Weinberg Partners (the “Company”) issued 1,320,319 shares of its Class A common stock in exchange for 1,319,000 Class A partnership units of PWP Holdings LP (“PWP OpCo”) and 1,319,000 shares of Class B common stock of the Company that were held by certain limited partners of PWP OpCo pursuant to the Amended and Restated Limited Partnership Agreement of PWP OpCo”

Eos Energy Enterprises, Inc. issued up to 570,000 shares of Common Stock of warrant to DOE for $0.01 per share.

“the Company will issue to the DOE a warrant to purchase up to 570,000 shares of Common Stock of the Company (the “Warrant”) on the third business day following the date the DOE Limited Consent Agreement and Amendment becomes effective (the “Issue Date”). The Warrant will expire on the fifth anniversary of the Issue Date (the “Termination Date”). Upon issuance, the Warrant will entitle the DOE to purchase up to an aggregate of 570,000 shares of Common Stock of the Company (the “Warrant Shares”) at an exercise price of $0.01 per share, subject to certain adjustments as described below.”

AMAZE HOLDINGS, INC. issued 80,513 shares of common stock of common stock to C/M Capital Master Fund, LP.

“In connection with those sales, the Company also issued a total of 80,513 shares of common stock to the Purchaser as commitment shares, pursuant to the terms of the Purchase Agreement.”

AMAZE HOLDINGS, INC. issued 10,735,000 shares of common stock of common stock to C/M Capital Master Fund, LP for aggregate purchase price of $4,867,585.

“From September 2 through November 14, 2025, Amaze Holdings, Inc. (the “Company”) issued and sold to C/M Capital Master Fund, LP (the “Purchaser”) 10,735,000 shares of common stock for an aggregate purchase price of $4,867,585, pursuant to that certain securities purchase agreement (the “Purchase Agreement”) dated as of May 6, 2025 by and between the Company and the Purchaser.”

Corebridge Financial, Inc. issued 500,000 shares of preferred stock.

“On November 18, 2025, Corebridge Financial, Inc. (the “Company”) closed the public offering of 500,000 shares of its 6.875% Fixed Rate Reset Non-Cumulative Preferred Stock, Series A (the “Series A Preferred Stock”).”

FrontView REIT, Inc. issued 750,000 shares of Series A Preferred Stock of preferred stock to Maewyn FVR II LP, Rebound Investment, LP and Petrus Special Situations Fund, L.P. for $100.00 per share for gross proceeds of approximately $75.0 million.

“and sell to the Purchasers a total of 750,000 shares of a new series of Series A Convertible Preferred Stock, par value $0.01 per share (the “Series A Preferred Stock”) for $100.00 per share for gross proceeds of approximately $75.0 million (the “Private Placement”). The sale of Series A Preferred Stock may occur in multiple tranches. On the terms and”

FIRST CITIZENS BANCSHARES INC /DE/ issued preferred stock.

“On November 14, 2025, First Citizens BancShares, Inc., a Delaware corporation (the “Company”), filed a certificate of designation (the “Certificate of Designation”) with the Secretary of State of the State of Delaware, establishing the rights, preferences, privileges, qualifications, restrictions and limitations of a new series of its preferred stock designated as the “7.000% Non-Cumulative Perpetual Preferred Stock, Series D””

ZION OIL & GAS INC issued not_applicable of warrant to not_applicable for not_applicable.

“On November 17, 2025, Zion Oil & Gas, Inc. (the “Company”) executed an Amendment to a certain Warrant Agent Agreement (the “Agreement”) between the Company and Equiniti Trust Company, LLC, a New York limited liability trust company with offices at 55 Challenger Road, 2 nd Floor, Ridgefield Park, N.J. 07660 (“ Equiniti ”).”

Tenon Medical, Inc. issued Pre-Funded Warrants of warrant to certain accredited investors for combined offering price of $1.285 per Share and Warrant.

“(“Pre-Funded Warrants”), and common stock purchase warrants (the “Warrants”), each exercisable for one share of common stock of the Company, at a combined offering price of $1.285 per Share and Warrant to purchase one share of common stock. The Warrants have an exercise price of $1.16 per share and expire 3 years from the date of issuance. The”

Tenon Medical, Inc. issued Warrants to purchase 2,217,904 shares of warrant to certain accredited investors for combined offering price of $1.285 per Share and Warrant.

“(“Pre-Funded Warrants”), and common stock purchase warrants (the “Warrants”), each exercisable for one share of common stock of the Company, at a combined offering price of $1.285 per Share and Warrant to purchase one share of common stock. The Warrants have an exercise price of $1.16 per share and expire 3 years from the date of issuance. The”

Tenon Medical, Inc. issued 2,217,904 shares of common stock to certain accredited investors for combined offering price of $1.285 per Share and Warrant.

“The Company agreed to issue and sell an aggregate of 2,217,904 shares of common stock, par value $0.001 per share (the “Shares”), and/or pre-funded common stock purchase warrants (“Pre-Funded Warrants”), and common stock purchase warrants (the “Warrants”), each exercisable for one share of common stock of the Company, at a combined offering price of $1.285 per Share and Warrant to purchase one share of common stock.”

Greenpro Capital Corp. issued 150,000 shares of common stock to individual investors (accredited investors) for $1.30 per share, aggregate gross proceeds of $195,000.

“On November 14, 2025, Greenpro Capital Corp. (the “Company”) entered into subscription agreements (the “Subscription Agreements”) with individual investors identified in the Subscription Agreements (individually, the “Purchaser” and collectively, the “Purchasers”), providing for the private placement of an aggregate of 150,000 shares of the Company’s common stock, par value $0.0001 (the “Common Stock”), at a per share purchase price of $1.30 (the “Offering”) or aggregate gross proceeds of $195,000.”

FingerMotion, Inc. issued 190,000 shares of common stock to one individual for $1.50 per share for gross proceeds of $285,000.

“On November 14, 2025, FingerMotion, Inc. (the “Company”) issued 190,000 shares of common stock at a price of $1.50 per share to one individual due to the closing of a private placement for gross proceeds of $285,000.”

NextCure, Inc. issued up to an aggregate of 1,815,049 shares of Common Stock of warrant to certain institutional and accredited investors for $8.519 per Pre-Funded Warrant.

“(ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 1,815,049 shares of Common Stock (the “Pre-Funded Warrant Shares”) at a purchase price of $8.519 per Pre-Funded Warrant”

NextCure, Inc. issued 708,428 shares of common stock to certain institutional and accredited investors for $8.52 per share.

“On November 12, 2025, NextCure, Inc. (“NextCure” or the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”) for a private placement (the “Offering”) of an aggregate of (i) 708,428 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $8.52 per share”

Senmiao Technology Ltd issued 200,000 shares of common stock to a consultant.

“the Company issued 200,000 shares of the Common Stock to a consultant (the “Consultant Shares”, collectively with the SPA Shares”, the “Shares”) in exchange for the consultant’s services.”

Senmiao Technology Ltd issued 500,000 shares of common stock to certain non-U.S. investors (the "Purchasers") for $1.32 per share.

“the Company agreed to sell, and the Purchasers agreed to purchase, severally and not jointly, an aggregate of 500,000 shares (the “SPA Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”) at an offering price of $ 1.32 per share (the “Offering”).”

Ensysce Biosciences, Inc. issued 2,487 unregistered shares of Preferred Shares convertible into 1,094,078 shares of Common Stock of preferred stock to institutional investor for per share purchase price of $1,000, stated value $1,100.

“investor held the number of shares of common stock acquirable upon a complete exercise of the Warrant. In the Offerings, the per share purchase price of the Preferred Stock is $1,000 with a stated value of $1100, and the conversion price per share of Common Stock is $2.50, subject to adjustment. In no event will the total cumulative number of shares of common”

Lucid Group, Inc. issued convertible note to qualified institutional buyers for $975,000,000 aggregate principal amount.

“with the Base Notes, the “ notes ”). On November 12, 2025, the initial purchasers elected to exercise the option to purchase the Additional Notes in full, and a total of $975,000,000 aggregate principal amount of notes were issued on November 17, 2025. The notes were offered only to persons reasonably believed to be qualified institutional buyers (as defined”

VSEE HEALTH, INC. issued 941,352 shares of common stock to accredited institutional investor for exchange of a certain promissory note, in the principal amount (including the original issue discount of $55,555.56) of $555,555.56 and with a current balance o.

“On November 13, 2025, VSee Health, Inc. (the “ Company ”), entered into an exchange agreement (the “ Agreement ”) with an accredited institutional investor (the “ Holder ”), whereby the Holder agreed to exchange a certain promissory note, in the principal amount (including the original issue discount of $55,555.56) of $555,555.56 and with a current balance of $611,878.22, for 941,352 shares of the Company’s common stock, par value $0.0001 per share.”

VSEE HEALTH, INC. issued 50,000 shares of the Company’s common stock of common stock to an accredited institutional investor for aggregate purchase price of $201,000.

“the Investor purchased a convertible promissory note in the initial principal amount of $217,391 (the “Note”) and 50,000 shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”) for an aggregate purchase price of $201,000.”

Merlin, Inc. issued 1,666,668 shares of New Merlin Labs Preferred Stock and Closing Warrants to purchase a number of shares of New Merlin Labs Common Stock that is equal to 75% of of convertible note to Additional Closing PIPE Investors for aggregate purchase price not specified.

“Inflection Point and Merlin Labs also entered into Securities Purchase Agreements, dated November 17, 2025 (the “ Additional Closing PIPE Subscription Agreements ”), with certain accredited investors signatory thereto (the “ Additional Closing PIPE Investors ”), pursuant to which, among other things, the Additional Closing PIPE Investors agreed to purchase, and Inflection Point agreed to sell, an aggregate of 1,666,668 shares of New Merlin Labs Preferred Stock and Closing Warrants to purchase a number of shares of New Merlin Labs Common Stock that is equal to 75% of the amount of shares into which such shares of New Merlin Labs Common Stock underlying the New Merlin Labs Preferred Stock are initially convertible, in a private placement, on substantially the same terms as the Closing PIPE Subscription Agreement”

Merlin, Inc. issued 9,803,922 shares of New Merlin Labs Preferred Stock and a Closing Warrant to purchase a number of shares of New Merlin Labs Common Stock equal to the amount of of convertible note to accredited investors (Closing PIPE Investor and Additional Closing PIPE Investors) for aggregate purchase price of $100,000,000 (increase from $50,000,000) for the Closing PIPE Investment; aggregate purchase price for Additional Closing PIPE Inves.

“On November 17, 2025, Inflection Point and Merlin Labs entered into an amendment to the Closing PIPE Subscription Agreement with the Closing PIPE Investor (“ Amendment No. 1 to the Closing PIPE Subscription Agreement ”), pursuant to which the Closing PIPE Investor agreed to increase its Closing PIPE Investment to $100,000,000, for which it will receive 9,803,922 shares of New Merlin Labs Preferred Stock and a Closing Warrant to purchase a number of shares of New Merlin Labs Common Stock equal to the amount of shares into which such shares of New Merlin Labs Common Stock underlying the New Merlin Labs Preferred Stock are initially convertible, on the same terms and conditions as the Closing PIPE Subscription Agreement.”

ONTO INNOVATION INC. issued 641,771 shares of Common Stock of common stock to the Seller.

“the Company issued 641,771 shares of Common Stock to the Seller pursuant to the Purchase Agreement.”

IONIS PHARMACEUTICALS INC issued convertible note to initial purchasers for $770.0 million aggregate principal amount.

“On November 17, 2025, Ionis Pharmaceuticals, Inc. (the “Company”) completed its previously announced private offering (the “Offering”) of $770.0 million aggregate principal amount of 0.00% Convertible Senior Notes due 2030 (the “Notes”), including the exercise in full of the initial purchasers’ option to purchase up to an additional $70.0 million principal amount of Notes.”

BRAINSTORM CELL THERAPEUTICS INC. issued convertible note to Labrys Fund II, L.P. for principal amount of $143,750 (including $18,750 of original issue discount) and received funds of $121,500 after legal fees of $3,500.

“On November 10, 2025, Brainstorm Cell Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with Labrys Fund II, L.P., a Delaware limited partnership (“ Labrys ”), pursuant to which the Company issued to Labrys a promissory note (the “ Note ”) in the principal amount of $143,750 (including $18,750 of original issue discount) and received funds of $121,500 after legal fees of $3,500.”

NANOVIRICIDES, INC. issued Series A Common Stock Purchase Warrants to purchase up to 3,571,429 shares of Common Stock and Series B Common Stock Purchase Warrants to purchase up to 3,571,4 of warrant to a certain institutional investor.

“The information contained above in Item 1.01 relating to the issuance of the Common Warrants and the shares of Common Stock issuable thereunder is hereby incorporated by reference into this Item 3.02.”

XWELL, Inc. issued convertible note to holders of Series G Convertible Preferred Stock for senior secured convertible notes in the aggregate principal amount of $3,387,138.80.

“the Company agreed to exchange a portion of the Company’s outstanding shares of Series G Preferred Stock, including all accrued and unpaid dividends thereon equal to $1,553,806.00 in aggregate Stated Value, held by the Holders, for senior secured convertible notes in the aggregate principal amount of $3,387,138.80”

XWELL, Inc. issued preferred stock to holders of Series G Convertible Preferred Stock.

“the Company filed the Certificate of Amendment with the Secretary of State of the State of Delaware. The Certificate of Amendment amends the Certificate of Designations to (i) reduce the conversion price of the Series G Preferred Stock to $1.00, (ii) remove the restrictive covenant requiring the Company to maintain unencumbered, unrestricted cash and cash equivalents on hand in an amount equal to at least 200% of the shares of common stock, par value $0.01 per share (“Common Stock”), issuable upon conversion of the outstanding shares of Series G Preferred Stock, (iii) amend the definition of “Make-Whole Amount,” such that it now means an amount equal to the amount of additional dividends that would accrue at the dividend rate then in effect assuming for calculation purposes that the Stated Value as of the Closing Date remained outstanding through and including the Maturity Date (as defined in the Certificate of Designations), (iv) add certain anti-dilution provisions such that the Seri”

TELA Bio, Inc. issued up to 333,333 shares of warrant to Perceptive Credit Holdings V, LP for in connection with the Delayed Draw Loan.

“the Company will issue to Perceptive warrants to purchase up to 333,333 shares of its Common Stock, with an exercise price of $1.11”

Nuvve Holding Corp. issued warrants to purchase up to a number of shares of common stock equal to 100% of the shares of Common Stock issuable upon conversion of the shares of Preferred St of warrant to identified purchasers for issued as part of the Offering with aggregate purchase price of $4,500,000.

“of Common Stock issuable upon conversion of the shares of Preferred Stock (the “Warrants”) with an aggregate stated value of $5,000,000, for an aggregate purchase price of $4,500,000 (the “Offering”). Pursuant to the Purchase Agreement, the Company agreed to hold a special meeting of stockholders on or prior to December 31, 2025, for the purposes of obtaining”

Nuvve Holding Corp. issued 5,000 shares of newly-designated Series A Convertible Preferred Stock of preferred stock to identified purchasers for aggregate purchase price of $4,500,000.

“On November 14, 2025, Nuvve Holding Corp. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with the purchasers identified therein (collectively, the “Purchasers”) providing for the issuance and sale to the Purchasers of (i) 5,000 shares of newly-designated Series A Convertible Preferred Stock (the “Preferred Stock”) and (ii) warrants to purchase up to a number of shares of common stock of the Company (the “Common Stock”) equal to 100% of the shares of Common Stock issuable upon conversion of the shares of Preferred Stock (the “Warrants”) with an aggregate stated value of $5,000,000, for an aggregate purchase price of $4,500,000 (the “Offering”).”

ASP Isotopes Inc. issued convertible note to certain institutional and individual investors for approximately $64.3 million.

“On November 7, 2025, Quantum Leap Energy LLC (“QLE”), a wholly owned subsidiary of ASP Isotopes Inc. (“ASPI”), entered into a Convertible Note Purchase Agreement (the “Purchase Agreement”) with certain institutional and individual investors (collectively, the “Purchasers”), to issue and sell to the Purchasers convertible promissory notes of QLE (the “QLE 2025 Notes”) in an offering to accredited investors under Regulation D or Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), or investors who are not a person in the United States or a U.S. Person (within the meaning of Rule 902(k) of Regulation S promulgated under the Securities Act) for approximately $64.3 million of QLE 2025 Notes.”

Centuri Holdings, Inc. issued approximately $75 million of shares of Common Stock of common stock to Icahn Partners LP and Icahn Partners Master Fund LP for a price per share equal to the Offering Price.

“On November 11, 2025, the Company entered into a common stock purchase agreement (the “Private Placement Agreement”) with Icahn Partners LP and Icahn Partners Master Fund LP, investment entities affiliated with Carl C. Icahn (collectively, the “Icahn Investors”), pursuant to which the Company agreed to issue and sell approximately $75 million of shares of Common Stock (the “Private Placement Shares”) to the Icahn Investors at a price per share equal to the Offering Price in a transaction exempt from registration under the Securities Act (the “Concurrent Private Placement”).”

Smart Powerr Corp. issued 17,000,000 shares of common stock included in 17,000,000 units of unit to certain accredited investors for per Unit purchase price to $1.305, increasing the gross proceeds to an aggregate of $22,185,000.

“On November 3, 2025, the Company and the Investors entered into an amendment to the securities purchase agreement (the “First Amendment”), pursuant to which the parties agreed to amend the per Unit purchase price to $1.305, increasing the gross proceeds to an aggregate of $22,185,000.”

Strategy Inc issued 7,750,000 shares of preferred stock for gross proceeds from the Offering were approximately €620.0 million (or $716.8 million).

“shares of a new class of its capital stock titled “10.00% Series A Perpetual Stream Preferred Stock” (the “STRE Stock”). The gross proceeds from the Offering were approximately €620.0 million (or $716.8 million) and the net proceeds from the Offering were approximately €608.8 million (or $703.9 million), after deducting the underwriting discounts and commissions and”

Seagate Technology Holdings plc issued approximately 4.3 million ordinary shares of common stock to holders of $500 million principal amount of exchangeable notes for $500 million principal amount of notes exchanged for approximately $503.4 million in cash and approximately 4.3 million ordinary shares.

“the aggregate of 4,313,941 ordinary shares issued in the Exchanges were issued pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), afforded by Section 4(a)(2) of the Securities Act in transactions not involving any public offering”

GoPro, Inc. issued common stock to Nicholas Woodman, through a trust for $2 million.

“Nicholas Woodman, the company’s founder and CEO, has made a direct investment of $2 million through the purchase of Class A common stock from the company via a trust affiliated with Mr. Woodman.”

Premier Air Charter Holdings Inc. issued 5,710 shares of Series A Preferred Stock of preferred stock to Prime Loan for $366,549 of debt.

“the Company agreed to settle $366,549 of debt in exchange for 5,710 shares of Series A Preferred Stock”

Premier Air Charter Holdings Inc. issued 39,970 shares of Series A Preferred Stock of preferred stock to Innoworks Employment Services, Inc. for $2,565,646 of debt.

“the Company agreed to settle $2,565,646 of debt in exchange for 39,970 shares of Series A Preferred Stock”

Voyager Technologies, Inc./DE issued convertible note to initial purchasers for $435,000,000 aggregate principal amount.

“13(a) of the Exchange Act. ☐ Item 1.01. Entry Into a Material Definitive Agreement. Indenture and Notes On November 12, 2025, Voyager Technologies, Inc. (the “ Company ”) issued $435,000,000 aggregate principal amount of its 0.75% Convertible Senior Notes due 2030 (the “ Notes ”). The Notes were issued pursuant to, and are governed by, an indenture (the “ Indenture”

AEON Biopharma, Inc. issued Pre-Funded Warrants, Warrants and True-Up Warrants of warrant to certain investors for $0.0001 per share for Pre-Funded Warrants, $1.09392 per share for Warrants.

“The Pre-Funded Warrants are being offered in lieu of shares of Common Stock and each Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of $0.0001 per share.”

AEON Biopharma, Inc. issued 1,964,905 Shares of common stock to certain investors for $0.9116 per Share.

“to purchase shares of Common Stock, and (iv) True-Up Warrants (as defined below) to purchase shares of Common Stock. The purchase price to be paid by the Investors will be $0.9116 per Share (or $0.9115 per Pre-Funded Warrant in lieu of Shares). The first closing of the Private Placement is expected to occur the week of November 17, 2025 (the “First”

MSD Investment Corp. issued 12,494,794 shares of common stock to the Company's stockholders (accredited investors) for aggregate offering price of approximately $300.0 million.

“On October 24, 2025, MSD Investment Corp. (the “ Company ”) delivered a capital drawdown notice to its stockholders relating to the sale of 12,494,794 shares (the “ Shares ”) of the Company's common stock, par value $0.001 per share (the “ Common Stock ”) for an aggregate offering price of approximately $300.0 million. The Shares were issued on November 7, 2025.”